vs

Side-by-side financial comparison of Axogen, Inc. (AXGN) and Beta Bionics, Inc. (BBNX). Click either name above to swap in a different company.

Axogen, Inc. is the larger business by last-quarter revenue ($61.5M vs $27.6M, roughly 2.2× Beta Bionics, Inc.). Axogen, Inc. runs the higher net margin — -31.9% vs -79.3%, a 47.4% gap on every dollar of revenue. On growth, Beta Bionics, Inc. posted the faster year-over-year revenue change (56.6% vs 26.6%).

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...

Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.

AXGN vs BBNX — Head-to-Head

Bigger by revenue
AXGN
AXGN
2.2× larger
AXGN
$61.5M
$27.6M
BBNX
Growing faster (revenue YoY)
BBNX
BBNX
+30.1% gap
BBNX
56.6%
26.6%
AXGN
Higher net margin
AXGN
AXGN
47.4% more per $
AXGN
-31.9%
-79.3%
BBNX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
AXGN
AXGN
BBNX
BBNX
Revenue
$61.5M
$27.6M
Net Profit
$-19.6M
$-21.9M
Gross Margin
75.2%
59.5%
Operating Margin
Net Margin
-31.9%
-79.3%
Revenue YoY
26.6%
56.6%
Net Profit YoY
-410.8%
23.6%
EPS (diluted)
$-0.38
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXGN
AXGN
BBNX
BBNX
Q1 26
$61.5M
$27.6M
Q4 25
$59.9M
$32.1M
Q3 25
$60.1M
$27.3M
Q2 25
$56.7M
$23.2M
Q1 25
$48.6M
$17.6M
Q4 24
$49.4M
Q3 24
$48.6M
Q2 24
$47.9M
Net Profit
AXGN
AXGN
BBNX
BBNX
Q1 26
$-19.6M
$-21.9M
Q4 25
$-13.2M
$-13.5M
Q3 25
$708.0K
$-14.2M
Q2 25
$579.0K
$-16.9M
Q1 25
$-3.8M
$-28.7M
Q4 24
$450.0K
Q3 24
$-1.9M
Q2 24
$-1.9M
Gross Margin
AXGN
AXGN
BBNX
BBNX
Q1 26
75.2%
59.5%
Q4 25
74.1%
59.0%
Q3 25
76.6%
55.5%
Q2 25
74.2%
53.8%
Q1 25
71.9%
50.9%
Q4 24
76.1%
Q3 24
74.9%
Q2 24
73.8%
Operating Margin
AXGN
AXGN
BBNX
BBNX
Q1 26
Q4 25
-16.3%
-50.2%
Q3 25
3.2%
-62.5%
Q2 25
3.0%
-85.5%
Q1 25
-3.4%
-105.7%
Q4 24
4.1%
Q3 24
-0.6%
Q2 24
-0.9%
Net Margin
AXGN
AXGN
BBNX
BBNX
Q1 26
-31.9%
-79.3%
Q4 25
-22.0%
-41.9%
Q3 25
1.2%
-52.1%
Q2 25
1.0%
-72.6%
Q1 25
-7.9%
-162.5%
Q4 24
0.9%
Q3 24
-3.8%
Q2 24
-4.0%
EPS (diluted)
AXGN
AXGN
BBNX
BBNX
Q1 26
$-0.38
$-0.49
Q4 25
$-0.28
$-0.16
Q3 25
$0.01
$-0.33
Q2 25
$0.01
$-0.39
Q1 25
$-0.08
$-0.93
Q4 24
$-0.00
Q3 24
$-0.04
Q2 24
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXGN
AXGN
BBNX
BBNX
Cash + ST InvestmentsLiquidity on hand
$82.7M
$199.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$244.8M
$271.2M
Total Assets
$289.5M
$304.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXGN
AXGN
BBNX
BBNX
Q1 26
$82.7M
$199.5M
Q4 25
$41.5M
$219.1M
Q3 25
$35.8M
$228.7M
Q2 25
$29.9M
$249.7M
Q1 25
$22.1M
$231.5M
Q4 24
$33.5M
Q3 24
$24.5M
Q2 24
$21.1M
Total Debt
AXGN
AXGN
BBNX
BBNX
Q1 26
Q4 25
$48.4M
Q3 25
$48.2M
Q2 25
$47.9M
Q1 25
$47.7M
Q4 24
$47.5M
Q3 24
$47.3M
Q2 24
$47.0M
Stockholders' Equity
AXGN
AXGN
BBNX
BBNX
Q1 26
$244.8M
$271.2M
Q4 25
$128.8M
$287.6M
Q3 25
$120.8M
$294.8M
Q2 25
$112.3M
$301.6M
Q1 25
$105.4M
$313.8M
Q4 24
$103.9M
Q3 24
$99.4M
Q2 24
$95.7M
Total Assets
AXGN
AXGN
BBNX
BBNX
Q1 26
$289.5M
$304.4M
Q4 25
$221.7M
$328.7M
Q3 25
$216.4M
$330.0M
Q2 25
$205.5M
$330.0M
Q1 25
$196.2M
$338.0M
Q4 24
$203.7M
Q3 24
$192.0M
Q2 24
$188.9M
Debt / Equity
AXGN
AXGN
BBNX
BBNX
Q1 26
Q4 25
0.38×
Q3 25
0.40×
Q2 25
0.43×
Q1 25
0.45×
Q4 24
0.46×
Q3 24
0.48×
Q2 24
0.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXGN
AXGN
BBNX
BBNX
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$-1.4M
FCF MarginFCF / Revenue
-2.3%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXGN
AXGN
BBNX
BBNX
Q1 26
Q4 25
$3.0M
$-8.6M
Q3 25
$3.2M
$-8.7M
Q2 25
$7.7M
$-13.6M
Q1 25
$-13.2M
$-20.0M
Q4 24
$8.7M
Q3 24
$3.9M
Q2 24
$4.2M
Free Cash Flow
AXGN
AXGN
BBNX
BBNX
Q1 26
$-1.4M
Q4 25
$1.8M
$-10.5M
Q3 25
$1.7M
$-10.0M
Q2 25
$7.0M
$-15.4M
Q1 25
$-13.4M
$-20.3M
Q4 24
$8.1M
Q3 24
$3.3M
Q2 24
$3.3M
FCF Margin
AXGN
AXGN
BBNX
BBNX
Q1 26
-2.3%
Q4 25
3.0%
-32.8%
Q3 25
2.8%
-36.7%
Q2 25
12.4%
-66.2%
Q1 25
-27.7%
-115.1%
Q4 24
16.3%
Q3 24
6.8%
Q2 24
6.8%
Capex Intensity
AXGN
AXGN
BBNX
BBNX
Q1 26
Q4 25
2.1%
5.9%
Q3 25
2.5%
4.7%
Q2 25
1.3%
7.7%
Q1 25
0.5%
1.9%
Q4 24
1.4%
Q3 24
1.2%
Q2 24
1.9%
Cash Conversion
AXGN
AXGN
BBNX
BBNX
Q1 26
Q4 25
Q3 25
4.55×
Q2 25
13.35×
Q1 25
Q4 24
19.41×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons